title: Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model.
abstract: BACKGROUND
  As endothelin binds to ET(A) receptors, it stimulates vascular smooth muscle cell proliferation and may thus be pivotally involved in the pathogenesis of restenosis. This study assessed the ability of a potent and selective ET(A) antagonist to reduce neointimal hyperplasia in a porcine coronary artery stented injury model.
  
  
  RESULTS
  Fifty-five pigs were randomized to receive placebo or the oral ET(A)-selective antagonist ABT147627 twice daily for 28 days in one of three doses: 0.75 mg/kg (low), 3.75 mg/kg (mid), and 10.0 mg/kg (high). Each underwent oversized stent deployment in two randomly assigned major epicardial coronary arteries. Three animals (5.5%) died as a consequence of stent thrombosis within 24 hours of the procedure. The remaining 52 animals (13 pigs per group) survived without complication until predetermined euthanasia at 28 days. In the placebo group, mean injury score was 1.73+/-0.80, with a mean neointimal response of 0.45+/-0.24 mm. By comparison, the low-dose group had a similar mean injury score of 1.79+/-0.75 with reduced neointimal response, 0.36+/-0.22 mm (P<0.01). Mean injury score in the mid-dose animals was significantly greater than in the placebo group (1.94+/-0.92; P<0.05). The neointimal hyperplasia associated with this injury was less than with placebo, although the difference did not reach statistical significance (0.40+/-0.25 mm; P=0.05). In the high-dose pigs, mean injury score was also significantly greater than in the placebo arm (1.93+/-0.73; P<0.05). Despite this, neointimal response was also significantly less (0.37+/-0.37 mm; P<0.01).
  
  
  CONCLUSIONS
  Oral, selective ET(A) receptor antagonism significantly reduced neointimal hyperplasia forming over porcine coronary stented injuries in the first 28 days. This strategy may have clinical potential for the limitation and treatment of coronary restenosis after percutaneous revascularization.
authors.affiliation: Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, Minn, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: McKenna
authors.forename: S E
authors.initials: SE
authors.lastname: Burke
authors.forename: T J
authors.initials: TJ
authors.lastname: Opgenorth
authors.forename: R J
authors.initials: RJ
authors.lastname: Padley
authors.forename: L J
authors.initials: LJ
authors.lastname: Camrud
authors.forename: A R
authors.initials: AR
authors.lastname: Camrud
authors.forename: J
authors.initials: J
authors.lastname: Johnson
authors.forename: P J
authors.initials: PJ
authors.lastname: Carlson
authors.forename: A
authors.initials: A
authors.lastname: Lerman
authors.forename: D R
authors.initials: DR
authors.lastname: Holmes
authors.forename: R S
authors.initials: RS
authors.lastname: Schwartz
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003327:Coronary Disease / Q000473:pathology* / Q000601:surgery; D003331:Coronary Vessels / Q000473:pathology*; D004195:Disease Models, Animal; D065128:Endothelin Receptor Antagonists; D006965:Hyperplasia / Q000209:etiology / Q000517:prevention & control; D011897:Random Allocation; D012044:Regression Analysis; D015607:Stents; D013552:Swine; D017539:Tunica Intima / Q000473:pathology*
chemical_list: D065128:Endothelin Receptor Antagonists